Sanofi S.A., FR0000120578

Sanofi stock holds steady as investors weigh recent earnings and guidance

Published on 09/21/2026 at 11:32 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Sanofi stock trades around EUR 74 on Euronext Paris as of September 21, 2026, while analysts project upside with a three month consensus target above EUR 90. Recent quarterly figures and guidance keep fundamentals in focus for long term investors.

Modern pharmaceutical sterile fill-and-finish manufacturing facility interior with glass vial-filling machines and cleanroom workers in white suits — Sanofi FR0000120578 photorealistic sterile fill-and-finish facility with vial-filling machines and cleanroom workers, Illustration mit AI erstellt.

Sanofi stock (ISIN FR0000120578) is trading close to EUR 74 on Euronext Paris as of September 21, 2026, leaving the French pharmaceutical group roughly one quarter below the average three month analyst target of about EUR 93.

Sanofi stock around EUR 74 on Euronext Paris

Price data from Euronext-linked portals show Sanofi shares changing hands at about EUR 74.06 on Euronext Paris in early trading on September 21, 2026, with the quote recorded around 09:35 CET and intraday moves remaining narrow at that point.

A Nordic market overview from Placera on September 21, 2026, also lists Sanofi at EUR 74.08, flat on the day and down about 10.4 percent year to date, underlining that the stock has lagged the broader healthcare sector in 2026.

Analyst consensus points to upside versus current price

According to French portal Boursorama, the three month analyst consensus price objective for Sanofi stands at EUR 93.02 as of August 18, 2026, implying a potential gain of around 25.6 percent from levels near EUR 74.

The same consensus overview shows a distribution of recommendations skewed toward positive ratings, with a majority in the Buy and Reinforce categories and fewer calls to lighten or sell the position, although the precise count of analysts behind the target is not detailed in the summary.

Stock performance and quality scores in recent comparisons

An investment ideas article from the American Association of Individual Investors compares Eli Lilly and Sanofi and assigns Sanofi a Quality Score of 65, categorized as Strong, alongside a Momentum Score of 35 and an Earnings Estimate Score of 38, which is described as Negative. As AAII outlines, these metrics suggest solid underlying business quality but more cautious momentum and earnings revision trends for Sanofi compared with some US peers.

Closing price and investor takeaways

With Sanofi stock trading around EUR 74 on Euronext Paris as of September 21, 2026, against an analyst consensus target of about EUR 93 over the next three months, investors face a familiar trade off between near term share price weakness and longer term confidence in the company’s pipeline and earnings power.